Atlantic announces agreement with Credit Agricole.HALF MOON BAY, Calif.--(BUSINESS WIRE)--Sept. 17, 1996--Atlantic Pharmaceuticals Inc. (Nasdaq Small Cap: ATLC ATLC Arbitrary Transmission Line Calculator ATLC Atomic Trades and Labor Council ATLC Air Transport Label Catalog ATLC Advanced Technology Licensing Company ) today announced it has entered into an agreement with the U.S. subsidiary of Union d'Etudes et D'Investissements (UI), the merchant bank of Credit Agricole, the second largest banking house in Europe. Under terms of the agreement, UI USA Inc. will represent Atlantic's technologies to leading European pharmaceutical and biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. companies. "We are looking forward with great enthusiasm to this collaboration, which represents a significant opportunity for Atlantic," said J.D. Lindjord, president and chief executive officer of Atlantic. "UI USA and Credit Agricole have well-established track records of being able to expedite commercial agreements between U.S. companies and the European pharmaceutical industry." Credit Agricole, based in Paris, has more than $350 billion in assets and recently acquired control of Indosuez, another large French bank. UI, also based in Paris, invests in private companies in Europe and advises European companies It may never be fully completed or, depending on its its nature, it may be that it can never be completed. However, new and revised entries in the list are always welcome. This is a list of companies from the countries in the European Union. on mergers, acquisitions, private placements, and strategic alliances. Similarly, UI USA, based in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , advises U.S. companies looking to acquire or merge with European companies or to establish joint collaborations and strategic alliances in Europe. Atlantic Pharmaceuticals, based in Half Moon Bay, is a biopharmaceutical company developing pharmaceutical and biomedical products for a variety of therapeutic areas. Currently, Atlantic is developing novel technologies in the areas of cataract cataract, in medicine, opacity of the lens of the eye, which impairs vision. In the young, cataracts are generally congenital or hereditary; later they are usually the result of degenerative changes brought on by aging or systemic disease (diabetes). removal, antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). gene therapy, prevention of vascular restenosis following coronary angioplasty angioplasty (ăn`jēōplăs'tē), any surgical repair of a blood vessel, especially balloon angioplasty or percutaneous transluminal coronary angioplasty, a treatment of coronary artery disease. , and anti-inflammatory/analgesic drugs. As with any company developing novel therapeutics, Atlantic may make certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed due, among other things, to those risks described in the company's reports on Form 10-QSB and 10-KSB. -0- Editor's Notes: For more information on Atlantic's novel technologies and unique corporate vision, as well as biographical information on its management team and a copy of this release, visit Atlantic's homepage on the Internet at http://www.atlan.com. This release is also available at http://www.noonanrusso.com. A fact sheet on Atlantic is also available via fax through October 1 by calling 212/696-4455 ext. 329 and requesting document number 900. CONTACT: Atlantic Pharmaceuticals Inc., Half Moon Bay J.D. Lindjord, 415/726-1327 e-mail: mail@atlan.com or Noonan/Russo Communications Inc., New York 212/696-4455 Rich Tammero (media), ext. 222 Amy Martini (investor), ext. 255 e-mail: mail@noonanrusso.com |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion